Publikationen, an denen er mitarbeitet José Alcamí Pertejo (15)

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2017

  1. Monocytes phenotype and cytokine production in human immunodeficiency virus-1 infected patients receiving a modified vaccinia ankara-based HIV-1 vaccine: Relationship to CD300 molecules expression

    Frontiers in Immunology, Vol. 8, Núm. JUL

2015

  1. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 6, pp. 1833-1842

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2010

  1. Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants

    Antiviral Research, Vol. 88, Núm. 2, pp. 152-159

2008

  1. Optimal use of maraviroc in clinical practice

    AIDS, Vol. 22, Núm. 17, pp. 2231-2240

2007

  1. Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression

    Virus Genes, Vol. 34, Núm. 2, pp. 111-116

2006

  1. New findings on transcription regulation across different HIV-1 subtypes

    AIDS Reviews, Vol. 8, Núm. 1, pp. 9-16

2002

  1. Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma

    Journal of Clinical Microbiology, Vol. 40, Núm. 4, pp. 1518-1521

  2. Herramientas de laboratorio para individualizar el tratamiento: Resistencias y niveles de fármacos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 20, Núm. SUPPL.2, pp. 35-47

  3. Multicenter study of the LCx® HIV RNA Quantitative Assay - A new competitive reverse transcriptase-PCR which targets pol genomic region of HIV-1 for the measurement of type B, non-type B and group O HIV-1 RNA

    Clinical Chemistry and Laboratory Medicine, Vol. 40, Núm. 7, pp. 698-704

2001

  1. GESIDA Consensus document on the use of resistance studies in clinical practice

    Enfermedades infecciosas y microbiología clínica

1999

  1. CCR5 genotype and HIV-1 infection in perinatally-exposed infants

    Journal of Infection, Vol. 38, Núm. 1, pp. 9-11

1998

  1. LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression

    Virus Research, Vol. 57, Núm. 1, pp. 11-20